Form D · Biotechnology
Promedix, Inc.
Portland, OR · CIK 0001858277
Offering snapshot reported Dec 17, 2024 · SEC filing
- Reported sold
- $200K Offering amount: $200K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 2, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 17, 2024 | Initial | $200,000 | No comparison | 1 | SEC filing |
| Sep 11, 2023 | Amendment | $310,000 | $260,000vs Oct 31, 2022 | 4 | SEC filing |
| Sep 11, 2023 | Amendment | $162,778 | $112,778vs Oct 31, 2022 | 3 | SEC filing |
| Oct 31, 2022 | Initial | $50,000 | No comparison | 1 | SEC filing |
| Oct 31, 2022 | Initial | $50,000 | No comparison | 1 | SEC filing |
| Apr 23, 2021 | Initial | $250,000 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-532265
Source: Form D, filed Dec 17, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Steven Baker | Executive |
| Scott Filer | Director, Executive |
| Matthew Hansen | Director, Executive |
| Robert Jenks | Executive |
| Andrew Kibler | Director, Executive |
| David Sheridan | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4640 Sw Macadam Avenue Suite 200
Portland, OR, 97239
Portland, OR, 97239